Pro Dex Q1 2027 earnings

PDEX · 2026-10-29 16:04 AMC ET · 8-K on SEC · 10-Q on SEC

Revenue grew 11% to $20.6 million, but net income fell 35% to $3.0 million due to a $3.2 million swing in unrealized investment gains and higher operating expenses.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$20.6M+11%—Ex. 99.1, income statement
EPS (GAAP)$0.92-34%—Ex. 99.1, income statement

Revenue breakdown

not stated in the 8-K

Margins and costs

  • Gross margin 33% (prior 29%, change +4 pp)
  • Operating expenses $3.34M (+48% YoY)
  • One-offs in the quarter Unrealized gain on investments $73,000 (vs $3.3M prior); Credit loss expense $64,000 (vs recovery $2 prior)
  • Effective tax rate 9.8% (prior 24.8%)
  • Non-GAAP bridge Adds back share-based compensation, unrealized gains/losses, lease expense, loan fees, and credit losses to reconcile to operating cash flow.

KPIs

MetricActualPrior quarterPrior yearChange
Net cash provided by operating activities$6.49M—$2.31M+181%
Cash and cash equivalents$11.76M$8.19M—+44%
Inventory$21.90M$21.46M—+2%
Accounts receivable$17.51M$21.21M—-17%

Guidance

not stated in the 8-K

What drove it

  • Revenue story Medical device revenue increased $3.3M driven by the next-generation handpiece, offset by a $1.7M decrease in legacy handpiece repairs; APM contributed $511K.
  • EPS story EPS declined primarily due to a $3.2M swing in unrealized investment gains and higher operating expenses.
  • One-off check Unrealized gain on investments $73,000 (vs $3.3M prior year); Credit loss expense $64,000 (vs recovery $2 prior year).

The good

  • Revenue grew 11% YoY driven by new handpiece and APM
  • Operating income grew 13% YoY despite higher expenses
  • Operating cash flow increased 181% YoY to $6.49M

The bad

  • Net income fell 35% YoY due to volatile investment gains
  • Operating expenses increased 48% YoY driven by APM ops and engineering
  • Accounts receivable decreased $3.7M, potentially indicating collection issues

The ugly

  • none

Open questions

  • What caused the $3.7M decrease in accounts receivable?
  • What is the outlook for the Monogram/Zimmer Biomet validation units?
  • Will the volatility in investment gains persist?
Full release

Earnings: PDEX — filed 2026-10-29

Pro Dex Inc (PDEX) · Form 8-K, Item 2.02 · Filed · SEC filing

Contact: Richard L. Van Kirk,

Chief Executive Officer

(949) 769-3200

For Immediate Release

PRO-DEX, INC. ANNOUNCES FISCAL 2027 FIRST

QUARTER RESULTS

IRVINE, CA,

October 29, 2026 - PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for its fiscal 2027 first quarter ended September 30, 2026.

The Company also filed its Quarterly Report on Form 10-Q for the first quarter of fiscal year 2027 with the Securities and Exchange Commission today.

Quarter Ended September 30, 2026

Net sales for the three months ended September 30, 2026, increased $2.1 million, or 11%, to $20.6 million from $18.5 million for the three months ended September 30, 2025. The increase is driven primarily by a $3.3 million increase in medical device revenue, inclusive of rebates, of which $1.8 million relates to the next-generation handpiece we sell to our largest customer, offset by a $1.7 million decrease in repairs of the legacy handpiece we sell to that customer, coupled with an increase in revenue of

$511,000 generated by the Company’s newly acquired subsidiary, Advanced Precision Machining, LLC (“APM”), exclusive of inter-company sales in the amount of $814,000 which are eliminated in consolidation.

Gross profit for the three months ended September 30, 2026, increased $1.5 million, or 28%, compared to the year-ago period. Gross margin increased by 4 percentage points to 33% during the three months ended September 30, 2026, compared to 29% during the corresponding year-ago period, due primarily as a result of favorable product mix.

Operating expenses (which include selling, general and administrative, and research and development expenses) for the quarter ended September 30, 2026, increased

$1.1 million, or 48%, to $3.3 million compared to $2.3 million for the prior fiscal year’s corresponding quarter. The increase relates to a $442,000 increase in engineering and a $642,000 increase in selling, general and administrative expenses. The increase in engineering relates to personnel costs as well as higher internal project expenditures. The increase inselling, general and administrative expense is primarily due to $466,000 of APM’s separate operations as well as $195,000 of higher personnel costs specifically related to accounting, mergers and acquisitions, human resources, and information technology.

Our operating income for the quarter ended September 30, 2026, increased $406,000, or 13%, to $3.5 million compared to $3.1 million for the prior fiscal year’s corresponding quarter. The increase reflects our increased gross profit, offset by our increased operating expenses, as described above.

Net income for the quarter ended September 30, 2026, decreased to $3.0 million, or $0.92 per diluted share, compared to net income of $4.7 million, or $1.40 per diluted share, for the quarter ended September 30, 2025. Our net income for the quarter ended September 30, 2026, contains unrealized gains on our marketable equity investments of $73,000, while our net income for the quarter ended September 30, 2025, includes unrealized gains on our marketable equity investments of $3.3 million. All of our investments are recorded at estimated fair value, and the period-to-period valuation can be highly volatile. For example, our investment in Monogram Technologies, Inc. was valued as of September 30, 2025 at the cash price we received in October 2025, upon its acquisition by Zimmer Biomet Holdings, Inc. We received $4.04 per share for each of the common shares we owned of Monogram, for a total of $8.9 million in cash proceeds.

CEO Comments

Richard L. (“Rick”)

Van Kirk, the Company’s President and Chief Executive Officer, commented, “We are pleased with our first quarter results and continued top line revenue growth.” Mr. Van Kirk concluded, “We are also pleased to be working with the Monogram and Zimmer

Biomet teams and expect to ship validation units later this fiscal year.”

About Pro-Dex, Inc.:

Pro-Dex, Inc. specializes in the design, development, and manufacture of autoclavable, battery-powered, and electric multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and maxocranial facial markets. We have patented adaptive torque-limiting technology and proprietary sealing solutions that appeal to our customers, primarily medical device distributors. Additionally, we provide engineering, quality, and regulatory consulting services to our customers. Our APM subsidiary manufactures parts and assemblies for the aerospace and defense industries in addition to providing several machined components to support Pro-Dex’s customers. Pro-Dex, Inc. also sells rotary air motors to a wide range of industries; however, these air motors comprise a de minimis portion of our business. Pro-Dex's products are found in hospitals and medical engineering labs around the world. For more information, visit the Company's websites at www.pro-dex.com and www.advanced-precision.com.

Financial statements

Income Statement

Three Months Ended September 30, — (In thousands, except share and per share amounts)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025
Net sales20,56018,530
Cost of sales13,70313,163
Gross profit6,8575,367
Operating expenses:
Selling, general and administrative expenses2,1321,490
Research and development costs1,210768
Total operating expenses3,3422,258
Operating income3,5153,109
Other income (expense):
Interest and dividend income5114
Unrealized gain on investments733,299
Interest expense-260-200
Total other income (expense)-1363,113
Income before income taxes3,3796,222
Provision for income taxes3311,542
Net income3,0484,680
Basic and diluted net income per share:
Basic net income per share0.951.43
Diluted net income per share0.921.4
Weighted-average common shares outstanding:
Basic3,206,3043,261,753
Diluted3,315,4153,338,805
Common shares outstanding3,203,3343,262,004

Balance Sheet

September 30, 2026 — (In thousands, except share amounts)

September 30, 2026June 30, 2026
Current Assets:
Cash and cash equivalents11,7598,192
Investments1,2301,150
Accounts receivable, net of allowance for credit losses of $285 and $349 at September 30, 2026 and June 30, 2026, respectively17,50721,205
Deferred costs2770
Inventory21,89921,458
Income taxes receivable1,081620
Prepaid expenses and other current assets443553
Total current assets53,94653,248
Land and building, net5,9445,967
Equipment and leasehold improvements, net5,3595,373
Right-of-use asset, net2,048602
Intangibles, net666686
Deferred income taxes1,5441,544
Investments497504
Goodwill6,5256,525
Other assets6060
Total assets76,58974,509
Current Liabilities:
Accounts payable5,3214,262
Accrued liabilities3,2244,366
Income taxes payable124124
Deferred revenue4426
Notes payable4,1714,205
Total current liabilities12,88412,983
Lease liabilities, net of current portion2,089627
Notes payable, net of current portion12,27013,266
Total non-current liabilities14,35913,893
Total liabilities27,24326,876
Shareholders’ Equity:
Retained earnings49,34647,633
Total shareholders’ equity49,34647,633
Total liabilities and shareholders’ equity76,58974,509

Cash Flow

From the 10-Q · Three Months Ended September 30, — (In thousands)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income3,0484,680
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization403311
Share-based compensation135161
Unrealized gain on marketable equity investments-73-3,299
Non-cash lease expense (recovery)-6-9
Amortization of loan fees43
Credit loss expense (recovery)-642
Changes in operating assets and liabilities:
Accounts receivable and other receivables3,762-1,803
Deferred costs42-8
Inventory-441649
Prepaid expenses and other assets110175
Accounts payable and accrued expenses14-12
Deferred revenue17-80
Income taxes-4611,540
Net cash provided by operating activities6,4902,310
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of equipment and improvements-346-98
Net cash used in investing activities-346-98
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal payments on notes payable-1,033-11,595
Proceeds from UMB Bank loans, net of origination fees9,438
Proceeds from stock option exercises and ESPP contributions5740
Principal payments on equipment finance leases-75
Payments of employee taxes on net issuance of common stock-926
Repurchases of common stock-600
Net cash used in financing activities-2,577-2,117

Statements herein concerning the Company's plans, growth, and strategies may include 'forward-looking statements' within the context of the federal securities laws.

Statements regarding the Company's future events, developments, and future performance (including the expected shipment of Monogram validation units) as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. The Company's actual results may differ materially from those suggested as a result of various factors.

Interested parties should refer to the risk factors and other disclosures concerning the operational and business concerns of the Company set forth in the Company's filings with the Securities and Exchange Commission.

(tables follow)

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Pro Dex earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.